Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stemulite Marketer Learns NAD Expects Prompt Replies

This article was originally published in The Tan Sheet

Executive Summary

Stemulite fitness dietary supplements marketer Metabolic Research Inc. finds that failing to reply promptly to a National Advertising Division inquiry can get a firm tossed from the self-regulatory frying pan into the FTC fire

You may also be interested in...



NAD tells Metabolic Research to drop claims

Metabolic Research disagrees with the National Advertising Division's recommendations to discontinue claims that people who take Stemulite experience "deep REM sleep, Increased Muscle Gain and Endurance, Increased Wellness and Energy." The firm said data in the New England Journal of Medicine and "similar resources" supports the claims. It added it "retained counsel to further review" claim documentation and has "every intention" of complying. NAD said a 17-person, 30-day study Metabolic Research submitted did not support the claims because it was too small, subjective and not placebo-controlled. The two got off to a rocky start when NAD attempted to contact the firm via a former employee at an incorrect address. The resulting delay did not give the firm enough time to response to NAD's request, the firm said. This prompted NAD to refer the case to the Federal Trade Commission (1"The Tan Sheet" Sept. 7, 2009). NAD reopened the case after the advertiser said it would participate

NAD tells Metabolic Research to drop claims

Metabolic Research disagrees with the National Advertising Division's recommendations to discontinue claims that people who take Stemulite experience "deep REM sleep, Increased Muscle Gain and Endurance, Increased Wellness and Energy." The firm said data in the New England Journal of Medicine and "similar resources" supports the claims. It added it "retained counsel to further review" claim documentation and has "every intention" of complying. NAD said a 17-person, 30-day study Metabolic Research submitted did not support the claims because it was too small, subjective and not placebo-controlled. The two got off to a rocky start when NAD attempted to contact the firm via a former employee at an incorrect address. The resulting delay did not give the firm enough time to response to NAD's request, the firm said. This prompted NAD to refer the case to the Federal Trade Commission (1"The Tan Sheet" Sept. 7, 2009). NAD reopened the case after the advertiser said it would participate

NAD tells Metabolic Research to drop claims

Metabolic Research disagrees with the National Advertising Division's recommendations to discontinue claims that people who take Stemulite experience "deep REM sleep, Increased Muscle Gain and Endurance, Increased Wellness and Energy." The firm said data in the New England Journal of Medicine and "similar resources" supports the claims. It added it "retained counsel to further review" claim documentation and has "every intention" of complying. NAD said a 17-person, 30-day study Metabolic Research submitted did not support the claims because it was too small, subjective and not placebo-controlled. The two got off to a rocky start when NAD attempted to contact the firm via a former employee at an incorrect address. The resulting delay did not give the firm enough time to response to NAD's request, the firm said. This prompted NAD to refer the case to the Federal Trade Commission (1"The Tan Sheet" Sept. 7, 2009). NAD reopened the case after the advertiser said it would participate

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel